4579 — RaQualia Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for RaQualia Pharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	—	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,107	2,776	2,918	1,901	3,108
Cost of Revenue
Gross Profit	969	2,456	2,686	1,656	2,482
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,595	2,088	2,117	2,260	3,344
Operating Profit	-488	688	801	-359	-237
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-528	881	851	-294	-358
Provision for Income Taxes
Net Income After Taxes	-607	756	723	-324	-495
Net Income Before Extraordinary Items
Net Income	-607	756	723	-324	-495
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-607	756	723	-324	-495
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-28.9	36.8	37.1	-14.3	-12.8
Dividends per Share